Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chugai Pharmaceutical CoSTU:CUP -5.35%95 5-Year Yield-on-Cost % is 4.07 as of Aug. 01, 2026, which is 48% above its 10-year median of 2.75. GuruFocus rates STU:CUP with a GF Score™ of 95/100 and a GF Value™ of €42.02 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 512 Drug Manufacturers companies, Chugai Pharmaceutical Co ranks better than 68.16% on this metric.
The historical rank and industry rank for Chugai Pharmaceutical Co's 5-Year Yield-on-Cost % or its related term are showing as below:
STU:CUP'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.17 Med: 2.75 Max: 5.32
Current: 4.07
During the past 13 years, Chugai Pharmaceutical Co's highest Yield on Cost was 5.32. The lowest was 1.17. And the median was 2.75.
STU:CUP's 5-Year Yield-on-Cost % is ranked better than 68.16% of 512
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs STU:CUP: 4.07
Chugai Pharmaceutical Co (STU:CUP) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Chugai Pharmaceutical Co 5-Year Yield-on-Cost % Related Terms
STU:CUP vs LLY, JNJ, ABBV: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chugai Pharmaceutical Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Chugai Pharmaceutical Co's 5-Year Yield-on-Cost % falls into.
Chugai Pharmaceutical Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Chugai Pharmaceutical Co (STU:CUP) has a 5-Year Yield-on-Cost % of 4.07 as of Aug. 01, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chugai Pharmaceutical Co and its competitors. This is 48% above median its historical median of 2.75. Over the past decade, Chugai Pharmaceutical Co's 5-Year Yield-on-Cost % has ranged from 1.17 to 5.32. According to the industry distribution chart, Chugai Pharmaceutical Co ranks #163 out of 512 companies in the Drug Manufacturers industry, placing it in the top 31.8%.
Is Chugai Pharmaceutical Co's 5-Year Yield-on-Cost % too high?
Chugai Pharmaceutical Co's current 5-Year Yield-on-Cost % of 4.07 is 48% above median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 5.32. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. Chugai Pharmaceutical Co's value of 4.07 is 75.4% above this industry median. Based on the distribution chart, Chugai Pharmaceutical Co ranks #163 out of 512 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Chugai Pharmaceutical Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's 5-Year Yield-on-Cost % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Chugai Pharmaceutical Co ranks #163 out of 512 companies for 5-Year Yield-on-Cost %. This puts Chugai Pharmaceutical Co in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.32. Chugai Pharmaceutical Co's value of 4.07 is 75.4% above this benchmark. Historically, Chugai Pharmaceutical Co's own 5-Year Yield-on-Cost % has ranged from 1.17 to 5.32 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 2.32, Chugai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chugai Pharmaceutical Co's current 5-Year Yield-on-Cost % of 4.07 is 75.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chugai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chugai Pharmaceutical Co's current 5-Year Yield-on-Cost % is 4.07, which is 48% above median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (STU:CUP) is currently considered Modestly Undervalued. The stock's GF Value™ is €42.02, compared to a current price of €36.79 — trading 12.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.07, which is 48% above median its 10-year median of 2.75 and 75.4% above the Drug Manufacturers industry median of 2.32. Chugai Pharmaceutical Co's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Chugai Pharmaceutical Co (STU:CUP), the current 5-Year Yield-on-Cost % is 4.07 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (STU:CUP) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of €36.79 is trading 12.4% below its estimated GF Value™ of €42.02.
GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for STU:CUP:
5-Year Yield-on-Cost %: 4.07 (48% above median its 10-year median of 2.75)
GF Value™: €42.02 vs. price of €36.79 (12.4% below fair value)
Industry Position: 75.4% above the Drug Manufacturers median (#163 of 512)
No single metric tells the full story. See the STU:CUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
95GF Score
Get the complete analysis for STU:CUP
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CUP has been successfully added to your 
